AstraZeneca advances the science of infectious disease protection at ECCMID 2024
Real-world effectiveness data on Beyfortus reinforce the impact of passive immunisation protecting infants from RSV hospitalisation.Updated real-world data demonstrate continued risk of severe COVID-19 outcomes among immunocompromised populations.AstraZeneca will showcase new clinical, real-world and early science data across its Vaccines & Immune Therapies portfolio at the 34[th] European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Barcelona, Spain from 27-30 April 2024. The company has 19 abstracts at the event, including four oral presentations and four late-